Plain-English translation of NCT06719011 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Obesity research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new injectable medication called NNC0174-1213 to see if it can help treat overweight and obesity. Researchers want to understand whether this medication is safe, how the body processes it, and how well it works. You would receive either the new medication, a similar experimental medication called cagrilintide, or a placebo (a dummy injection with no active ingredients).
Current treatment options for overweight and obesity are limited, and researchers are working to develop new medications that could help people manage their weight more effectively. This trial is an early-stage study to see if this new medication could become a safe and useful option.
The study has two parts lasting about one year total. In Part A, you would receive a single injection and be monitored for safety and how your body responds. In Part B, you would receive multiple injections over time while researchers continue to track your health and how the medication works. Throughout the study, you would have regular clinic visits for blood tests, physical exams, and check-ins with the research team.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
United States